Clovis Oncology, Inc. was a big mover last session, as its shares rose almost 22% on the day. The upside followed the release of Tesaro, Inc.’s positive Phase 3 clinical trial results for Niraparib, a PARP inhibitor. Clovis Oncology is developing rucaparib, which is also a PARP inhibitor. This led to far more shares changing hands than in a normal session. Yesterday’s rally reverses the downtrend for the company, as the stock is now down almost 11%.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Clovis Oncology has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Is CLVS going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Clovis Oncology, Inc. was a big mover last session, as its shares rose almost 22% on the day. The upside followed the release of Tesaro, Inc.’s positive Phase 3 clinical trial results for Niraparib, a PARP inhibitor. Clovis Oncology is developing rucaparib, which is also a PARP inhibitor. This led to far more shares changing hands than in a normal session. Yesterday’s rally reverses the downtrend for the company, as the stock is now down almost 11%.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Clovis Oncology has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Is CLVS going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>